Streetbeat News

Stock Prices

ABT

Abbott Laboratories has projected its Q4 2024 adjusted earnings per share (EPS) to be between $1.31 and $1.37, surpassing the consensus estimate of $1.20.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:35 am

ABT

Abbott has updated its full-year 2024 adjusted EPS guidance to a range of $4.64 to $4.70, slightly narrowing its previous range of $4.61 to $4.71. This new guidance aligns closely with the consensus estimate of $4.66.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:34 am

MS

Morgan Stanley reported Q3 2024 earnings of $1.88 per share, surpassing the analyst estimate of $1.58. Sales reached $15.38 billion, exceeding the expected $14.41 billion and marking a 15.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:31 am

ALZN

Alzamend Neuro (NASDAQ:ALZN) has released the full data set from its Phase 2A trial for AL001, a treatment for dementia related to Alzheimer's. The study found the treatment to be safe and well-tolerated, paving the way for further clinical trials. Alzamend plans to conduct five additional trials to compare lithium levels in the brain with those from a marketed lithium salt.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has confirmed positive topline results from June 2023, identifying a maximum tolerated dose as assessed by an independent safety review committee.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has announced the full data set for its Phase IIA clinical trial of AL001, a treatment for dementia related to Alzheimer's. This development is a significant step in the company's research efforts.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

SYF

Synchrony Financial shares rose after the company reported better-than-expected Q3 results and increased its FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:29 am

INTC

JBHT

NVCR

QQQ

SPY

US stock futures indicate a mixed opening after a tech sell-off led by ASML's weak forecast. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) show slight premarket gains. J.B. Hunt Transport Services (JBHT) and NovoCure (NVCR) see significant premarket rises due to positive earnings and FDA approval, respectively. Intel (INTC) declines on Qualcomm's investment delay. Oil prices continue to pressure energy stocks.

Portfolio Pulse from Shanthi Rexaline

October 16, 2024 | 11:29 am

NVCR

The FDA has approved NovoCure's Optune Lua, a portable device that uses tumor-treating electric fields, for use with certain inhibitors or docetaxel in treating metastatic non-small cell lung cancer. The approval follows positive results from the Phase 3 LUNAR study, showing significant improvements in overall survival rates. NovoCure's stock (NVCR) rose by 26.20% following the news.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:28 am

OMC

Omnicom Group's shares are trading lower following the release of their Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:28 am